Results 221 to 230 of about 264,642 (338)

Papel das moléculas PD-1 e PD-L1 na regulação da resposta aguda dos linfócitos T CD4+ e CD8+ à infecção pelo Plasmodium chabaudi. [PDF]

, 2012
Letícia Sarturi Pereira Severi
openalex   +1 more source

Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin‐mediated Phagocytic Effects for Lung Cancer Treatment

Advanced Science, EarlyView.
Repurposing cardiac glycosides (CGs) significantly strengthens the efficacy of anti‐CD47 antibody for lung cancer treatment by boosting macrophage phagocytosis. This novel combination blocks the “don't eat me” signal and increases dual “eat‐me” signals, Fc‐FcγR and cell surface expression of calreticulin (ecto‐CRT).
Zi‐Han Ye, Wei‐Bang Yu, Mu‐Yang Huang, Yan‐Yan Chen, Le‐Le Zhang, Chung‐Hang Leung, Xiao‐Lei Zhang, Zhenghai Tang, Ting Li, Jin‐Jian Lu   +9 more
wiley   +1 more source

Smohaze‐Upregulated RFWD3 Competes with TRIM24 to Stabilize TREX1 and Reduce Cytosolic dsDNA in Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
The E3 ubiquitin ligase RFWD3 binds the exonuclease TREX1 and protects it from TRIM24‐mediated ubiquitination and degradation, leading to the eradication of intracellular dsDNA, inhibition of the cGAS‐STING pathway, and immunosuppressive microenvironment of lung cancer.
Xue‐Yan Shi, Yu‐Ke Shen, Meng‐Yao Lv, Yu Sun, Yong‐Fang Lin, Zheng Wang, Xiao‐Liang Jie, Zheng Liu, Yang‐Tong Liu, Yang‐Xin Fu, Zhenhua Ren, Gui‐Zhen Wang, Guang‐Biao Zhou   +12 more
wiley   +1 more source

FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy. [PDF]

Oncogene
Gong L, Tian L, Li H, Zhou K, He H, Xiao S, Zhu Y, Gong Z, Cui K, Zhang Y.   +9 more
europepmc   +1 more source

PD-L1: A novel target

Cancer Research, Statistics, and Treatment, 2022
openaire   +2 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. [PDF]

Mol Cancer
Mandal K, Barik GK, Santra MK.
europepmc   +1 more source

LIVER DENDRITIC CELLS INDUCES FOXP3+ TREG AND LIVER GRAFT TOLERANCE IN A PD-L1 DEPENDENT MANNER

, 2010
W. Li, Ramasamy Bakthavatsalam, Zhaohui Meng, James D. Perkins, Jorgé Reyes   +4 more
openalex   +1 more source

CircLRBA Promotes Epithelial‐Mesenchymal Transition, Immune Evasion, Chemoimmunotherapy Resistance and Metastasis Through Stabilizing Twist1

Advanced Science, EarlyView.
CircLRBA is highly expressed in breast cancer (BC) and associated with poor overall survival. Zeb1 mediated circLRBA facilitates BC cell proliferation, invasion, docetaxel (DTX) resistance and inhibits the infiltration of CD8+ T cell. CircLRBA could combine with SPOP to suppress the Twist1 ubiquitination degradation and enhances PD‐L1 transcription ...
Xiaosong Wang, Xin Yang, Lei Xing, Hang Chen, Fuming Xie, Bin Wang, Bowen Shi, Yan Yang, Junxia Chen   +8 more
wiley   +1 more source

PD-1/PD-L1 Inhibitors and Chemotherapy Synergy: Impact on Drug Resistance and PD-L1 Expression in Breast Cancer-Immune Cell Co-Cultures. [PDF]

Int J Mol Sci
Özen Eroğlu G, Erol Bozkurt A, Yaylım İ, Kuruca DS.   +3 more
europepmc   +1 more source